RELMADA THERAPEUTICS, INC. Cash Flow Statement
RLMD|1 years of annual SEC 10-K data (FY2013-FY2013)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid. All figures from audited SEC 10-K filings.
RELMADA THERAPEUTICS, INC. used $7,565 in operating cash flow and negative free cash flow of $5,765 in FY2013.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2013 |
|---|---|
| Net Income | -$12.1K |
| Operating Cash Flow | -$7.6K |
| Capital Expenditures | -$1.8K |
| Free Cash Flow | -$5.8K |
| FCF Margin | -72.6% |